Journal of Clinical Oncology, Vol 12, 1349-1357, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Follicular large-cell lymphoma: intermediate or low grade?

NL Bartlett, M Rizeq, RF Dorfman, J Halpern and SJ Horning
Department of Medicine, Stanford University School of Medicine, CA.

PURPOSE: To evaluate the benefit of anthracycline-based chemotherapy, identify prognostic factors, and determine the value of the International Prognostic Factors Index for patients with follicular large-cell (FLC) lymphoma. PATIENTS AND METHODS: This retrospective study includes 96 patients with FLC lymphoma treated at Stanford University Medical Center between 1969 and 1991. Fifty-five patients received doxorubicin plus cyclophosphamide-containing chemotherapy regimens, 21 patients received other chemotherapy regimens, 15 patients received radiotherapy only, and five patients received no initial therapy. Thirty-four patients had stage I or II disease and 62 patients had stage III or IV disease. RESULTS: With a median follow-up duration of 5.2 years (range, 1 to 18), the actuarial 5- and 10-year overall survival rates were 75% and 54%, with actuarial 5- and 10-year freedom from progression (FFP) rates of 53% and 42%, respectively. Patients treated with chemotherapy regimens that contained both doxorubicin and cyclophosphamide had a superior actuarial 10-year FFP rate (55% v 25%, P = .06) and overall survival rate (65% v 42%, P = .04) compared with patients treated with other chemotherapy regimens. Only one patient treated with doxorubicin plus cyclophosphamide relapsed after 3 years. In the multivariate analysis, discordant lymphoma and treatment with chemotherapy regimens not containing both cyclophosphamide and doxorubicin predicted for worse FFP and overall survival rates. In addition, poor performance status and increasing areas of diffuse histology predicted for a worse survival, while anemia and male sex predicted for a worse FFP. The age-specific International Index was useful in predicting outcome; however, few patients with FLC lymphoma had high-risk features. CONCLUSION: The plateau in FFP implies that patients with FLC lymphoma enjoy sustained remissions after standard anthracycline-based chemotherapy. FLC lymphoma should continue to be approached as an intermediate-grade lymphoma with curative intent.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. J. Overman, L. Feng, B. Pro, P. McLaughlin, M. Hess, F. Samaniego, A. Younes, J. E. Romaguera, F. B. Hagemeister, L. Kwak, et al. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma Ann. Onc., March 1, 2008; 19(3): 553 - 559. [Abstract] [Full Text] [PDF]

				A. K. Ganti, D. D. Weisenburger, L. M. Smith, C. P. Hans, R. G. Bociek, P. J. Bierman, J. M. Vose, and J. O. Armitage Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience Ann. Onc., June 1, 2006; 17(6): 920 - 927. [Abstract] [Full Text] [PDF]

				M. Ghielmini, O. Mora, P. McLaughlin, P. Solal-Celigny, and on behalf of the Scientific Committee of the FLIPI Does the FLIPI apply to grade 3 follicular lymphoma? Blood, June 15, 2005; 105(12): 4892 - 4893. [Full Text] [PDF]

				T. Katzenberger, G. Ott, T. Klein, J. Kalla, H. K. Muller-Hermelink, and M. M. Ott Cytogenetic Alterations Affecting BCL6 Are Predominantly Found in Follicular Lymphomas Grade 3B with a Diffuse Large B-Cell Component Am. J. Pathol., August 1, 2004; 165(2): 481 - 490. [Abstract] [Full Text] [PDF]

				C. P. Hans, D. D. Weisenburger, J. M. Vose, L. M. Hock, J. C. Lynch, P. Aoun, T. C. Greiner, W. C. Chan, R. G. Bociek, P. J. Bierman, et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival Blood, March 15, 2003; 101(6): 2363 - 2367. [Abstract] [Full Text] [PDF]

				A. G. Bosga-Bouwer, G. W. van Imhoff, R. Boonstra, A. van der Veen, E. Haralambieva, A. van den Berg, B. de Jong, V. Krause, M. C. Palmer, R. Coupland, et al. Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive Blood, February 1, 2003; 101(3): 1149 - 1154. [Abstract] [Full Text] [PDF]

				S. J. Horning Something Old, Something Few, Something Subjective, Something Deja Vu J. Clin. Oncol., January 1, 2003; 21(1): 1 - 2. [Full Text] [PDF]

				B. A. Peterson, G. R. Petroni, G. Frizzera, M. Barcos, C. D. Bloomfield, N. I. Nissen, D. D. Hurd, E. S. Henderson, G. P. Sartiano, J. L. Johnson, et al. Prolonged Single-Agent Versus Combination Chemotherapy in Indolent Follicular Lymphomas: A Study of the Cancer and Leukemia Group B J. Clin. Oncol., January 1, 2003; 21(1): 5 - 15. [Abstract] [Full Text] [PDF]

				E. Maartense, S. le Cessie, H. C. Kluin-Nelemans, P. M. Kluin, S. Snijder, P. W. Wijermans, and E. M. Noordijk Age-related differences among patients with follicular lymphoma and the importance of prognostic scoring systems: analysis from a population-based non-Hodgkin's lymphoma registry Ann. Onc., August 1, 2002; 13(8): 1275 - 1284. [Abstract] [Full Text] [PDF]

				G. Ott, T. Katzenberger, A. Lohr, S. Kindelberger, T. Rudiger, M. Wilhelm, J. Kalla, A. Rosenwald, J. G. Muller, M. M. Ott, et al. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3 Blood, May 15, 2002; 99(10): 3806 - 3812. [Abstract] [Full Text] [PDF]

				J. Rodriguez, P. McLaughlin, F.B. Hagemeister, L. Fayad, M.A. Rodriguez, M. Santiago, M. Hess, J. Romaguera, and F. Cabanillas Follicular Large Cell Lymphoma: An Aggressive Lymphoma That Often Presents With Favorable Prognostic Features Blood, April 1, 1999; 93(7): 2202 - 2207. [Abstract] [Full Text] [PDF]

				T. Philip, C. Guglielmi, A. Hagenbeek, R. Somers, H. Van Der Lelie, D. Bron, P. Sonneveld, C. Gisselbrecht, J.-Y. Cahn, J.-L. Harousseau, et al. Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma N. Engl. J. Med., December 7, 1995; 333(23): 1540 - 1545. [Abstract] [Full Text] [PDF]